Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Curis | CRIS | Nov 15, 2024 | 3.95 | -0.75 |
CURRENC Group | CURR | Nov 15, 2024 | 1.92 | 0.00 |
Curtiss-Wright | CW | Nov 15, 2024 | 358.35 | -0.80 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Nov 15, 2024 | 43.47 | +1.49 |
Cushman & Wakefield | CWK | Nov 15, 2024 | 13.84 | -1.91 |
Custom Truck One Source | CTOS | Nov 15, 2024 | 5.09 | -0.20 |
Customers Bancorp | CUBI | Nov 15, 2024 | 54.87 | -0.38 |
Customers Bancorp E Pref | CUBI-E | Nov 15, 2024 | 26.10 | -0.15 |
Customers Bancorp F Pref | CUBI-F | Nov 15, 2024 | 25.70 | 0.00 |
Cutera | CUTR | Nov 15, 2024 | 0.32 | -2.11 |
CVB Financial | CVBF | Nov 15, 2024 | 22.52 | -0.44 |
CVD Equipment | CVV | Nov 15, 2024 | 2.91 | -9.06 |
CVR Energy | CVI | Nov 15, 2024 | 18.82 | +0.37 |
Cvr Partners LP Unit | UAN | Nov 15, 2024 | 72.37 | +0.07 |
CVRx | CVRX | Nov 15, 2024 | 13.91 | -1.56 |
CVS Health | CVS | Nov 15, 2024 | 53.19 | -3.45 |
CXApp A | CXAI | Nov 15, 2024 | 1.39 | -2.80 |
CyberArk Software | CYBR | Nov 15, 2024 | 305.27 | +1.32 |
Cybin | CYBN | Nov 15, 2024 | 11.60 | +5.45 |
Cyclacel Pharmaceuticals | CYCC | Nov 15, 2024 | 0.37 | -4.91 |
Cyclacel Pharmaceuticals Pref | CYCCP | Nov 15, 2024 | 6.61 | -5.17 |
Cyclerion Therapeutics | CYCN | Nov 15, 2024 | 2.58 | +45.76 |
Cyclo Therapeutics | CYTH | Nov 15, 2024 | 0.70 | +13.71 |
Cyngn | CYN | Nov 15, 2024 | 5.89 | -16.81 |
Cytek Biosciences | CTKB | Nov 15, 2024 | 5.95 | -7.32 |
Cytokinetics | CYTK | Nov 15, 2024 | 50.22 | -8.19 |
Cytomed Therapeutics | GDTC | Nov 15, 2024 | 2.17 | +2.56 |
CytomX Therapeutics | CTMX | Nov 15, 2024 | 0.91 | -9.00 |
Cytosorbents | CTSO | Nov 15, 2024 | 0.90 | -5.78 |
D-MARKET Electronic Services & Trading ADR | HEPS | Nov 15, 2024 | 2.92 | -0.34 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.